Journals / European Archives of Medical Research / 2022 / Cilt: 38 - Sayı: 2

Indicators of Recurrence Before and After Transplantation in Patients who Underwent Liver Transplantation Due for Hepatocellular Carcinoma

Pages
138–143
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum alpha feto protein (AFP) values at postoperative 3rd, 6th, and 9th months were significantly higher (p=0.001, p=0.004, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Although the most effective current treatment method for hepatocellular carcinoma (HCC) is liver transplantation (LT), some patients may have a recurrence of HCC after transplantation.
📊
Key Findings & Data:Methods: Pre and post transplantation clinical, laboratory, imaging and histopathological data of 66 patients who underwent LT for HCC approximately 2017-2020 in our hospital were retrospectively reviewed.
💡
Conclusion & Impact:Serum alpha feto protein (AFP) values at postoperative 3rd, 6th, and 9th months were significantly higher (p=0.001, p=0.004, p
🔬Design:Review & Systematic Survey
📍Scope:2017-2020 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Although the most effective current treatment method for hepatocellular carcinoma (HCC) is liver transplantation (LT), some patients may have a recurrence of HCC after transplantation. In our study, we investigated the laboratory and histopathological factors that we think may predict HCC recurrence before and after transplantation in patients who underwent LT due to HCC. Methods: Pre and post transplantation clinical, laboratory, imaging and histopathological data of 66 patients who underwent LT for HCC approximately 2017-2020 in our hospital were retrospectively reviewed. The patients who developed recurrence were examined in detail. Results: Recurrence developed in seven (10.61%) of 66 patients who underwent LT due to HCC. The mean age of the patients with and without relapse was 60.14 and 58.63 years, respectively. Most patients who underwent LT were men, and all patients with recurrence were men. In patients with recurrence, maximum tumor diameter measured macroscopically (5 cm; 2.7 cm, p=0.002) and presence of lymphovascular invasion (42.9%; 10.2%, p=0.048) were significantly higher than those without recurrence. Serum alpha feto protein (AFP) values at postoperative 3rd, 6th, and 9th months were significantly higher (p=0.001, p=0.004, p

🔖

Cite This Article

BULUR, A., HACISALİHOĞLU, U. P., SEVMİŞ, M. (2022). Indicators of Recurrence Before and After Transplantation in Patients who Underwent Liver Transplantation Due for Hepatocellular Carcinoma. European Archives of Medical Research, Cilt: 38 - Sayı: 2, 138–143. https://ajindex.com/articles/510278

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Lee HW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol 2016;22:309-18
  2. Lai Q, Lerut JP. Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant 2014;19:229-34
  3. West CA, Black AP, Mehta AS. Analysis of hepatocellular carcinoma tissue for biomarker discovery. 2019 Aug 6. In: Hoshida Y, editor. Hepatocellular Carcinoma: Translational Precision Medicine Approaches [Internet]. Cham (CH): Humana Press; 2019. Chapter 5
  4. Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology 1994;20:33S-40S
  5. Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014;40:893-902
  6. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36
  7. Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant 2016;21:231-7
  8. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9
  9. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17(Suppl 2):S44-57
  10. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003;21:4329-35
  11. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012;48:599-641
  12. Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, et al. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology 2014;60:1637-44
  13. Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 201